MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) today announced that the United States Patent and Trademark Office has granted a patent that protects the semisynthetic production of homoharringtonine (Ceflatonin®) and its analogs and the use of these compounds in a treatment of leukemia. The U.S. 7,169,774 B2 patent, entitled “Cephalotaxane Derivatives and Their Processes of Preparation and Purification” provides ChemGenex and its partner, Stragen Pharma, with a proprietary position until 2019 in the United States.
